Your browser doesn't support javascript.
loading
Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation.
Volpes, Riccardo; Burra, Patrizia; Germani, Giacomo; Manini, Matteo Angelo; Caccamo, Lucio; Strignano, Paolo; Rizza, Giorgia; Tamè, Mariarosa; Pinna, Antonio Daniele; Calise, Fulvio; Migliaccio, Carla; Carrai, Paola; De Simone, Paolo; Valentini, Maria Filippa; Lupo, Luigi Giovanni; Cordone, Gabriella; Picciotto, Francesco Paolo; Nicolucci, Antonio.
Afiliación
  • Volpes R; Mediterranean Institute for Transplantation and High Specialization Therapies, Palermo, Italy.
  • Burra P; Multivisceral Transplant Unit (Gastroenterology), Department of Surgery, Oncology and Gastroenterology,Surgical and Gastroenterological Sciences, Padua University Hospital, Padua, Italy.
  • Germani G; Multivisceral Transplant Unit (Gastroenterology), Department of Surgery, Oncology and Gastroenterology,Surgical and Gastroenterological Sciences, Padua University Hospital, Padua, Italy.
  • Manini MA; 1st Division of Gastroenterology and Hepatology, Ca' Granda-Maggiore Polyclinic Hospital, Scientific Institute for Research, Hospitalization, and Health Care, Milan, Italy.
  • Caccamo L; 1st Division of Gastroenterology and Hepatology, Ca' Granda-Maggiore Polyclinic Hospital, Scientific Institute for Research, Hospitalization, and Health Care, Milan, Italy.
  • Strignano P; General Surgery and Liver Transplant Center, S. Giovanni Battista Hospital, Turin, Italy.
  • Rizza G; General Surgery and Liver Transplant Center, S. Giovanni Battista Hospital, Turin, Italy.
  • Tamè M; Liver and Multiorgan Transplantation, Department of General Surgery, Sant'Orsola-Malpighi Polyclinic, Bologna, Italy.
  • Pinna AD; Liver and Multiorgan Transplantation, Department of General Surgery, Sant'Orsola-Malpighi Polyclinic, Bologna, Italy.
  • Calise F; Hepatobiliary Surgery and Transplant Unit, Cardarelli Hospital, Naples, Italy.
  • Migliaccio C; Hepatobiliary Surgery and Transplant Unit, Cardarelli Hospital, Naples, Italy.
  • Carrai P; Department of General Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy.
  • De Simone P; Department of General Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy.
  • Valentini MF; General Surgery and Liver Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
  • Lupo LG; General Surgery and Liver Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
  • Cordone G; Hepatology Unit, AORN A. Cardarelli, Naples, Italy.
  • Picciotto FP; Hepatology Unit, AORN A. Cardarelli, Naples, Italy.
  • Nicolucci A; Center for Outcomes Research and Clinical Epidemiology, Via Tiziano Vecellio, 2, 65124, Pescara, Italy. nicolucci@coresearch.it.
Health Qual Life Outcomes ; 18(1): 99, 2020 Apr 10.
Article en En | MEDLINE | ID: mdl-32276633
BACKGROUND: Hepatitis B immunoglobulin (HBIG) therapy is available in intravenous (IV) or intra-muscular (IM) formulations. Recently, a subcutaneous (SC) formulation was introduced. This study evaluated changes in quality of life when liver transplant (LT) recipients were switched from IV or IM HBIG to the SC formulation. METHODS: This multicentre, observational study involved adults who had undergone LT at least 1 year prior to study entry. Quality of life was evaluated using the ITaLi-Q questionnaire, assessing the impact of HBIG therapy on daily activities and patient satisfaction, and the SF-36 Health Survey. Patients completed the questionnaires prior to switching from IV or IM HBIG to SC HBIG and 6 months later. RESULTS: Eighty-six patients were enrolled; before the switch, 68.6% were receiving IM HBIG and 31.4% IV HBIG. After 6 months, significant improvements in 7 of the 8 ITaLi-Q domains were found, particularly side effects, need for support to adhere to the therapy and satisfaction with the HBIG therapy. Significant improvements in several SF-36 domains were documented, including physical functioning, physical and emotional role limitations, pain, social functioning, physical and mental summary scores. CONCLUSIONS: The SC route of administration reduces side effects and their interference with daily life, ameliorates negative feelings, and increases patient autonomy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Calidad de Vida / Inmunoglobulinas / Factores Inmunológicos Tipo de estudio: Clinical_trials / Observational_studies Aspecto: Patient_preference Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Health Qual Life Outcomes Asunto de la revista: SAUDE PUBLICA Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Calidad de Vida / Inmunoglobulinas / Factores Inmunológicos Tipo de estudio: Clinical_trials / Observational_studies Aspecto: Patient_preference Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Health Qual Life Outcomes Asunto de la revista: SAUDE PUBLICA Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido